Molecular immunity to mycobacteria: knowledge from the mutation and phenotype spectrum analysis of Mendelian susceptibility to mycobacterial diseases  by Qu, Hui-Qi et al.
International Journal of Infectious Diseases 15 (2011) e305–e313Review
Molecular immunity to mycobacteria: knowledge from the mutation and
phenotype spectrum analysis of Mendelian susceptibility to mycobacterial
diseases
Hui-Qi Qu *, Susan P. Fisher-Hoch, Joseph B. McCormick
University of Texas Health Science Center at Houston, School of Public Health, Brownsville Campus, 80 Fort Brown, SPH Bldg, Brownsville, Texas 78520, USA
A R T I C L E I N F O
Article history:
Received 10 October 2010
Received in revised form 4 January 2011
Accepted 10 January 2011
Corresponding Editor: Sunit K. Singh,
Hyderabad, India
Keywords:
Mendelian susceptibility to mycobacterial
diseases
Interleukin-12
Interferon-gamma
IKBKG
S U M M A R Y
Understanding molecular immunity against mycobacterial infection is critical for the development of
effective strategies to control tuberculosis (TB), which is a major health issue in the developing world.
Host immunogenetic studies represent an indispensable approach to understand the molecular
mechanisms against mycobacterial infection. A superb paradigm is the identiﬁcation of rare mutations
causing Mendelian susceptibility to mycobacterial diseases (MSMD). Mutations in the interferon-
gamma (IFN-g) receptor genes are highly speciﬁc (although not exclusive) for mycobacterial infection.
Only dominant negative mutations of STAT1 have speciﬁc susceptibility to mycobacterial infection.
Mutations in the interleukin-12 (IL-12) signaling genes have phenotypes with non-speciﬁcity. Current
studies highlight a complex molecular network in antimycobacterial immunity, centered on IFN-g
signaling.
 2011 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Tuberculosis (TB) is a disease caused by the transmission of TB
bacilli in aerosols. Before the advent of effective chemotherapy in
themid-twentieth century, more than half of patients with TB died
within 5 years. The most common disease-causing species of TB
bacilli is Mycobacterium tuberculosis (MTB). The World Health
Organization (WHO) estimates that more than two billion people
in the world (one third of the world’s population) were infected by
MTB in 2009, and about one in 10 will develop disease (http://
www.who.int/tb/en/).
MTB infection initiates from the inhalation of aerosolized
infectious droplets into the alveoli of the lungs. On entering the
alveoli, MTB are phagocytosed by alveolar macrophages. The
innate immune system of the host and the virulence of MTB are
two key components that determine the outcome of the MTB
infection. The alveolar macrophage with its phagosomes is both
the site of elimination ofMTB and the site of TB bacillus replication.
Depending on host and bacterial factors, either the MTB will
multiply and destroy the infected macrophages, and infect more
macrophages, or be eliminated by the macrophage phagosomes.* Corresponding author. Tel.: +1 956 882 7006; fax: +1 956 882 5152.
E-mail address: Huiqi.Qu@uth.tmc.edu (H.-Q. Qu).
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doi:10.1016/j.ijid.2011.01.004Subsequently, infected macrophages migrate to the draining
lymph nodes, present MTB antigens to naı¨ve CD4+ T-lymphocytes,
and activate Th1 cellular immunity.
Dendritic cells play a critical role in priming the Th1 response.1
The activation of adaptive immunity takes 2–4 weeks. The Th1
response activates macrophages and the delayed-type hypersen-
sitivity (DTH) reaction, which is a double-edged sword with the
beneﬁcial effect of eliminatingMTB and the harmful effect of tissue
damage.2 Activated macrophages and lymphocytes accumulate at
the site of infection and form granulomas. Caseous necrosis can be
seen at the center of the granuloma, and occurs as a result of tissue
damage caused by the DTH reaction. If MTB disseminate before the
activation of adaptive cellular immunity, or the local infection
cannot be contained by the cellular immune responses, symptom-
atic primary TB will develop.
Adaptive cellular immunity against MTB infection is critical to
prevent primary TB. By inducing adaptive cellular immunity,
bacille Calmette–Gue´rin (BCG, named after the two pioneers who
developed the virulence-reduced live vaccine of Mycobacterium
bovis) vaccination has been successfully used in the prevention of
primary TB in children.3–6 However, BCG is not helpful to clear
MTB. MTB can remain dormant in granulomas for decades. During
the lifetime of the host, a number of situationsmay impair the host
immunity systemically (e.g., AIDS, diabetes, aging, etc.) or locally
(e.g., silicosis or smoking), and cause the reactivation of MTB andses. Published by Elsevier Ltd. All rights reserved.
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mechanisms underlying this complex process is critical for the
development of effective prevention and treatment measures.
Mendelian susceptibility to mycobacterial diseases (MSMD)
Familial atypical mycobacteriosis (FAM, MIM 209950) is a rare
congenital condition characterized by familial inherited immuno-
deﬁciency to mycobacterial infection, which is more popularly
known as Mendelian susceptibility to mycobacterial diseases
(MSMD). Mutations causing MSMD have been identiﬁed in several
genes. Because of the lethal effects of the MSMD mutations, the
frequenciesof thesemutations areextremely rare (<1/million).7 The
identiﬁcation of these MSMD mutations not only enables precise
diagnosis and guided treatment for MSMD, but also highlights the
central molecular mechanisms of host immunity to mycobacterial
infection, which is a superb paradigm for clarifying the molecular
immune mechanisms of a disease by the genetics approach.
MSMD has simple Mendelian inheritance patterns, i.e., auto-
some dominant, autosome recessive, or X-linked inheritance.
Clinically, MSMD is characterized by serious disseminated infec-
tion in early childhood of low virulence mycobacteria, most
commonly BCG vaccine. The patients are resistant to infectionwith
most other bacteria, fungi, and parasites. The Mendelian inheri-
tance suggests the disease is controlled by a single mutation. Both
patterns of autosome inheritance and X-linked inheritance suggest
that a mutation causing MSMD can be from either an autosome
gene or an X-chromosome gene. This selective susceptibility to
mycobacterial infection demonstrates the critical roles of mutated
genes in immunity against mycobacteria.
The BCG vaccine is comprised of virulence-attenuated M. bovis
sub-strains, and was ﬁrst developed by Albert Calmette and
Camille Gue´rin at the beginning of the twentieth century by
culturing virulent M. bovis on bile-containing medium for 230
serial passages. The attenuation of virulence results from the
mutations involving M. bovis proteins mediating its virulence,
including ESX-1, PDIM/PGL, and PhoP.8 Live BCG bacilli induce the
adaptive cellular immune responses by the cross-reactive antigens
of MTB bacilli. The immunogenicity of BCG is mediated byM. bovis
proteins different from those mediating its virulence. BCG
vaccination is a highly cost-effective intervention against severe
childhood TB, and is signiﬁcantly associatedwith a reduction in the
incidence of pulmonary TB and extrapulmonary disease in earlyTable 1
Genes involved in interferon-gamma (IFN-g) and interleukin-12 (IL-12) signaling
Gene symbol Gene name
1. Genes involved in IFN-g signaling
IFNG Interferon-gamma
IFNGR1a Interferon-gamma receptor-1
IFNGR2a Interferon-gamma receptor-2
JAK1 Janus kinase 1
JAK2 Janus kinase 2
STAT1a Signal transducer and activator of transcription-1
2. Genes involved in IL-12 signaling
IL12A Interleukin 12 subunit p35
IL12Ba Interleukin-12 subunit p40
IL12RB1a Interleukin-12 receptor beta-1 chain
IL12RB2 Interleukin 12 receptor, beta 2 chain
TYK2a Tyrosine kinase 2
JAK2 Janus kinase 2
STAT4 Signal transducer and activator of transcription 4
3. Other
IKBKGa Inhibitor of kappa light polypeptide gene enhancer
in B-cells, kinase gamma
a Genes with MSMD (MIM 209950) mutations.childhood, such as meningitis and miliary TB.3–6 The BCG
vaccination is not efﬁcacious in the prevention of pulmonary TB
in adolescents and adults, as it does not prevent the establishment
of primary infection or reactivation of latent MTB.5,9,10 The
administration of BCG vaccination in neonates is relatively safe.
However, in individuals with MSMD mutations, disseminated
infection and bacteremia may develop.
Seven genes have been identiﬁed with MSMDmutations. Six of
the seven genes are involved in the signaling of two cytokines, i.e.,
interferon-gamma (IFN-g) and interleukin-12 (IL-12). The other
gene, IKBKG, participates in the regulation of IL-12 and IFN-g
signaling, and other immune processes by the nuclear factor kappa
B (NF-kB) pathway. The major components involved in the
signaling of these two cytokines are listed in Table 1. Among
these signaling components, the three Janus tyrosine kinases, JAK-
1, JAK-2, and TYK-2, are involved in the signaling of a number of
cytokines besides IFN-g and IL-12. STAT1mediates the signaling of
both IFN-g and IFN-a/b, and STAT4 mediates the signaling of both
IL-12 and interleukin-23 (IL-23).
Functional impact of the MSMD mutations
Mutations leading to MSMD are listed in the Supplementary
Information (Table S1). The mutations have different impacts on
gene structure and function.
Deletion/insertion
Based on DNA structure changes, three types of deletion/
insertion (del/ins) mutations can be seen, i.e. deletion, insertion,
and combined deletion/insertion. In the combined deletion/inser-
tion, e.g., c.1440_1447delins16 in the IL-12 receptor beta-1 chain
gene (IL12RB1),11 a DNA fragment from the 1440th to 1447th
nucleotide in the IL12RB1 coding sequence is deleted, and a different
fragment of 16 nucleotides is inserted in the same position.
The del/ins mutations have different impacts on the protein
sequence. An in-frame del/ins mutation does not change the
protein sequence downstream of the mutation site. For example,
the c.295_306del in the interferon-gamma receptor-1 gene
(IFNGR1, encoding IFNgR1)12 is a deletion of 12 nucleotides, or
four amino acid codons. In contrast, if the deleted or inserted
nucleotides are not in triplets, the protein open reading frame will
be shifted from the mutation site. A frame-shift del/ins oftenChromosome position Nucleotide position (NCBI Build 37.2)
12q14 Chr12: 68548550.68553521
6q23–q24 Chr6: 137518621.137540567
21q22 Chr21: 34775202.34809828
1p32.3–p31.3 Chr1: 65298906.65432187
9p24 Chr9: 4985245.5128183
2q32 Chr2: 191833762.191878976
3q25.33–q26 Chr3: 159706629.159713806
5q31.1–q33.1 Chr5: 158741791.158757481
19p13 Chr19: 18170371.18197697
1p31.3–p31.2 Chr1: 67773047.67862583
19p13.2 Chr19: 10461204.10491248
9p24 Chr9: 4985245.5128183
2q32.2–q32.3 Chr2: 191894306.192015925
Xq28 ChrX: 153770459.153793261
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in the IFNGR1 gene,13,14 which causes a frame-shift from the 8th
codon, and produces a premature stop codon at six amino acids
downstream. A premature termination codon may have two
functional effects, i.e., the production of a truncated protein or
accelerated messenger RNA (mRNA) degradation by nonsense-
mediated decay (NMD). NMD is a protective mRNA surveillance
mechanism to prevent the expression of truncated or erroneous
protein by inducing the degradation of abnormal mRNA.15 An
abnormal mRNA that activates the NMD pathway by the presence
of a premature termination codon is degraded. Neither the mRNA
translation initiation complex is formed, nor is the mRNA available
for translation.
Splice site mutation
In the nascent mRNA precursors synthesized by gene tran-
scription, intronic regions need to be removed from heterogeneous
nuclear RNA (hnRNA) to produce functional mRNA. hnRNA
splicing, integrated in the uniﬁed gene expression process,16 is
mediated by the spliceosomes. The 50 splice site (splice-donor site)
and the 30 splice site (splice-acceptor site) of an intronic region
have highly conserved consensus sequences, i.e., GT at the 50 end
and AG at the 30 end. Mutations at the canonical splice sites cause
the failure of intron splicing, and consequent exon skipping. Exon
skipping may produce a premature termination codon, which can
induce NMD. For example, the splice-donor site mutation
c.200+1G>A at intron 2 of the IFNGR1 gene17,18 has the highly
conserved GT dinucleotide replaced by AT, which abolishes the 50
splice site and causes exon 2 skipping. The exon 2 skipping
produces a stop codon immediately downstream.
Missense mutation
Missense mutations usually refer to single nucleotide muta-
tions that cause an amino acid change. Compared to frame-shift or
splice site mutations, missense mutations tend to have less impact
on gene function. However, a single amino acid change in a
conserved protein functional domain or at a critical functional site
may have a dramatic impact on gene function. For example, an
intra-chain disulﬁde bridge between Cys77 and Cys85 in the IFN-g
receptor a (IFNgR1, or IFNgRa) is essential for binding with IFN-
g.19 The missense mutations, c.230G>A (Cys77Tyr) and c.254G>A
(Cys85Tyr), abolish the disulﬁde bridge and cause complete
deﬁciency of IFNgR1 activity.12,20
Theoretically, the functional effect of a missense mutation
can be predicted based on the sequence conservation across
different species and the distance of the properties of two amino
acids. A highly conserved region across different species, which
can be located by multiple sequence alignments of orthologs,
suggests its functional importance. The distance of two amino
acids can be assessed by their physiochemical properties21 or
evolutionary properties.22 Computer programs, e.g., SIFT23 and
PolyPhen,24 can assist in the prediction of the functional effect of
a missense mutation. SIFT makes the prediction based on
sequence homology and physical properties of amino acids
(http://sift.jcvi.org). PolyPhen predicts the function by protein
structure analysis (http://genetics.bwh.harvard.edu/pph/). The
combined usage of different algorithms can improve the
prediction.
Nonsense mutations and start codon mutations
A nonsense mutation refers to the single nucleotide mutation
that replaces an amino acid codon with a premature stop codon,
which may produce a truncated protein (e.g., c.832G>T in theIFNGR1 gene25) or induce NMD (e.g., c.347C>A in the IFNGR1
gene26,27).
The mutation c.2T>A in IFNGR1 is in the start AUG codon. This
mutation destroys the proper translation initiation site. For gene
translation, analternative and less efﬁcient translation initiation site
has to be used. A translation initiation site has the highly conserved
consensus sequence, RCCAUGG, known as the Kozak sequence.28
The A nucleotide of the AUG start codon is referred to as position 1,
and the preceding C nucleotide is referred to as position 1. R at
position 3 (R3) represents A or G. The AUG is essential. The G at
position +4 (G+4) and R3 are highly conserved. The replacement of
G+4 or R3 with another nucleotide has a dramatic impact on
translation efﬁciency.29,30 During the initiation of translation,
eukaryotic initiation factors (eIFs) bind to the mRNA poly-A tail
andm7G cap, and recruit the ribosome 40S subunit carrying the eIF2
andmethionyl initiator transferRNA (Met-tRNAi). Thepre-initiation
complex scans the mRNA to ﬁnd the ﬁrst proper Kozak sequence.
The original translation initiation site on the IFNGR1 mRNA
(NM_000416.2: 101–107) has the highly efﬁcient Kozak sequence,
AGCAUGG. The c.2T>A mutation abolishes the original initiation
site, and causes the ribosome 40S subunit to continue the scanning
of the mRNA to ﬁnd an alternative initiation site. The next AUG
codon on the IFNGR1 mRNA, GUCAUGC (NM_000416.2:131–137),
does not have the conserved G+4. The third AUG codon, GAGAUGG
(NM_000416.2: 155–161), is a proper Kozak sequence. The study by
Wang and Rothnagel31 showed that A3 has higher translational
efﬁciency than G3 in a Kozak sequence. Therefore, this alternative
translation initiation site is predicted to be less efﬁcient than the
destroyed original one. Empirically, Kong et al. showed lower
protein expression by the alternative initiation site, while the
additional cryptic translation initiation site remained to be
identiﬁed.32 Because of the remnant expression of IFNgR1, the
patient with a homozygous c.2T>A mutation has the phenotype of
partial IFNgR1 deﬁciency.
IFN-g signaling in MSMD
IFN-g signaling
MSMD mutations have been identiﬁed in three genes involved
in IFN-g signaling, i.e., IFNGR1, the interferon-gamma receptor-2
gene (IFNGR2, encoding IFNgR2 or IFNgRb), and the signal
transducer and activator of transcription-1 gene (STAT1, encoding
STAT1) (Figure 1).
The IFN-g receptor on the cell surface is a complex comprised of
two different proteins, IFNgR1 and IFNgR2. From the N-terminal,
each protein has an extracellular region, a transmembrane region,
and an intracellular region. Without the binding of IFN-g, the
monomers of IFNgR1 and IFNgR2 do not associate with each other.
In the extracellular region of IFNgR1, there are two functional
domains, D1 and D2. These two domains bind the IFN-g ligand, and
interact with the extracellular region of IFNgR2 .33 In the
intracellular region of IFNgR1, the important functional domains
include a Janus kinase 1 (JAK-1) binding site and a STAT1 docking
site when phosphorylated.34 JAK-1 binds with IFNgR1 constitu-
tively. The extracellular domain of IFNgR2 has the function of
stabilizing the structure and function of the IFNgR1 extracellular
domain. The intracellular region of IFNgR2 contains a Janus kinase
2 (JAK-2) binding site, which associates with JAK-2 constitutive-
ly.35 The tyrosine kinase activities of JAK-1 and JAK-2 are
interdependent. Inactivated STAT1 exists in the cytoplasm as a
homodimer through the interaction of its N-terminal domain.36,37
With the binding of the homodimeric IFN-g, two IFNgR1
subunits form a homodimer. Consequently, two IFNgR2 subunits
are recruited to the IFNgR1 dimer. The binding of IFNgR2 to
IFNgR1 brings the two Janus tyrosine kinases into physical
[(Figure_1)TD$FIG]
Figure 1. The proteins involved in interferon-gamma (IFN-g) signaling. Without the binding of IFN-g, the IFN-g receptor subunits are not associated with each other. IFNgR1
binds with JAK-1, and IFNgR2 binds with JAK-2. STAT1 exists in the cytoplasm as a homodimer through the interaction of N-terminal domains.
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phosphorylates and activates the STAT1 docking site on IFNgR1.
The STAT1 SH2 domain binds to the docking site on IFNgR1, which
enables the Janus kinases to phosphorylate the Tyr701 at the C-
terminal tail segment of STAT1. Then, the phosphorylated STAT1
dissociates from the IFN-g receptor complex. The SH2 domain of
each STAT1 binds with the phosphorylated tail segment of the
other STAT1, and forms the active STAT1 homodimer.38 The active
STAT1 homodimer will translocate to the nucleus and regulate the
transcription of IFN-g induced genes. This process of IFN-g
signaling is shown in the Supplementary Information (Figure S1:
IFN-g signaling).
MSMD mutations in the IFN-g signaling genes
People with MSMD mutations in each of the IFN-g signaling
genes have either complete or partial deﬁciency of the encoded
protein. The inheritance model of the disease can be either
autosome-recessive or autosome-dominant. Autosome-dominant
inherited MSMD patients with mutations of the IFN-g signaling
genes always have partial gene deﬁciency. The partial gene
deﬁciency is from the dominant negative effect by the expression
of aberrant proteins. The aberrant proteins caused by the
dominant-negative mutations cannot mediate IFN-g signaling.
Instead, the aberrant proteins interrupt the function of the wild-
type protein, either by competition for the ligands or by effective
inactivation of the wild-type protein through the formation of
nonfunctional dimer. For example, the dominant-negative muta-
tions from the IFNGR1 gene express stable truncated proteins.25,39–
44 These truncated proteins have correct sequences for the
extracellular and transmembrane domains, thus have the capabil-
ity to compete for IFN-g and dimerize with wild-type IFNgR1.
Without the interruption by the aberrant proteins, the expression
of a singlewild-type allele is sufﬁcient for gene function. This point
is clearly demonstrated by the fact that heterozygous carriers of
the mutations abolishing gene expression are healthy.
Complete deﬁciency of IFNgR1 or IFNgR2 has a much worse
prognosis than partial deﬁciency.40 However, the immunodeﬁ-
ciency caused by the MSMD mutations from these two genes is
speciﬁc for susceptibility to mycobacterial infection. This speciﬁc-
ity highlights the critical function of IFN-g signaling for immunity
to mycobacteria.Mutations of STAT1 downstream of the IFN-g signaling
STAT1 participates in both the IFN-g signaling of mycobacterial
immunity and the IFN-a/b signaling of viral immunity, by
different modes. In IFN-g signaling, STAT1 acts as a homodimer.
In contrast, in IFN-a/b signaling, STAT1 acts with STAT2 and
interferon regulatory factor 9 (IRF-9) as the heterotrimeric
transcription factor, interferon-stimulated gene factor 3 (ISGF3).45
The mutations causing STAT1 deﬁciency have three different
phenotypes, i.e. recessive-inherited complete deﬁciency,46–48
recessive-inherited partial deﬁciency,49 and dominant-inherited
partial deﬁciency.47,50 IFN-g production in response to BCG and IL-
12 stimulation is normal in partial STAT1 deﬁciency,47 but
impaired in complete STAT1 deﬁciency.46
Three mutations have been reported to cause recessive-
inherited complete deﬁciency. Two mutations, c.1760_1761del
and c.1927insA, are frame-shift deletion/insertions. The
c.1760_1761del causes a frame-shift from the 587th codon and
produces a premature stop codon 17 amino acids downstream.48
The c.1927insA causes a frame-shift from the 643rd codon, and
produces a premature stop codon three amino acids down-
stream.46,47 Both mutations, truncating the SH2 tail and transac-
tivation domains of STAT1, abolish the protein expression by
inducing NMD. Another mutation c.1799T>C (Leu600Pro) is a
missense mutation that causes a critical amino acid change in the
SH2 domain.48 The SH2 domain is essential to form the active
STAT1 homodimer by binding with the phosphorylated tail of the
other STAT1. The missense Leu!Pro mutation at codon 600
abolishes the dimerization function of the SH2 domain, thus
causing complete STAT1 deﬁciency in individuals with homozy-
gous mutations. It is noteworthy that the mutated allele Pro600
has stable protein expression and that heterozygous individuals
with this mutation are healthy without a dominant negative
phenotype. Therefore, the SH2-mediated dimerization of STAT1 is
the key to the dominant negative effect of MSMD mutations.
The mutation c.2086C>T causes recessive-inherited partial
deﬁciency of STAT1. The c.2086C>T is a missense Pro!Ser
mutation at the 696th codon. The functional effect of this mutation
is from the regulation of gene expression rather than from the
change of amino acid or protein structure. This mutation impairs,
but does not abolish, STAT1mRNA splicing, probably by disrupting
an exonic splice enhancer.49
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inheritance, and all are missense mutations causing a single amino
acid change with dominant negative effect. The mutations,
c.958G>C and c.1389G>T, cause nonconservative amino acid
changes in the DNA binding domain.47 Another mutation
c.2117T>C causes a nonconservative amino acid change at the
STAT1 tail domain that interferes in the phosphorylation of
Tyr701.50 The aberrant proteins expressed by these mutations
have an intact SH2 domain that is able to dimerize with
phosphorylated wild-type STAT1, and they therefore manifest a
dominant negative effect by consuming wild-type STAT1 and
forming nonfunctional dimer when activated by IFN-g.
The diverse phenotypes of the STAT1mutations provide further
evidence for the central role of IFN-g signaling in mycobacterial
immunity. The recessive-inherited STAT1 deﬁciency, either partial
or complete, results in susceptibility to both mycobacterial and
viral infection, including herpes simplex virus-1 and Epstein–Barr
virus. This fact can be explained by the impaired signaling of both
IFN-g and IFN-a/b in individuals with homozygous mutations. In
contrast, the phenotype of dominant-inherited partial deﬁciency
has selective susceptibility to mycobacterial infection. This
selectivity points to the speciﬁc dominant-negative mechanism
in IFN-g signaling. In the IFN-g signaling pathway, the expression
of aberrant proteins by the mutated allele consumes the wild-type
STAT1 by forming nonfunctional dimer. However, in IFN-a/b
signaling, the wild-type STAT1 can form active ISGF3 that is
unaffected by the mutated protein.
IL-12 signaling in MSMD
IL-12 signaling
Mutations leading to MSMD have been identiﬁed in two genes
involved in IL-12 signaling, i.e., the IL-12 subunit p40 gene (IL12B)
and IL12RB1. The critical components involved in IL-12 signaling
are shown in Figure 2.
Compared to the IFN-g signaling complex, the IL-12 signaling
complex is more heterogeneous.51 The active form of IL-12 is a
heterodimer, comprised of a p35 subunit (encoded by the gene
[(Figure_2)TD$FIG]
Figure 2. The critical components involved in interleukin-12 (IL-12) signaling. IL12Rb1
cytoplasm as a homodimer through the interaction of the N-terminal domains. The acIL12A) and a p40 subunit (encoded by the gene IL12B).52 The p35
subunit is homologous to interleukin-6 (IL-6)53 and the p40
subunit is homologous to the extracellular domain of the IL-6
receptor (IL-6R).53 An active IL-12 receptor also requires two
heterogeneous components, i.e., the b1 subunit (encoded by
IL12RB1) and the b2 subunit (encoded by IL12RB2). Without the
presence of IL-12, the IL-12 receptor subunits do not bind to each
other. Each receptor subunit is associated with a Janus tyrosine
kinase. Theb1 subunit is associatedwith TYK-2 and theb2 subunit
is associated with JAK-2.54 Inactivated STAT4 exists in the
cytoplasm as a homodimer through the interaction of its N-
terminal domain.37
In the presence of IL-12, each IL-12R subunit binds with an
active IL-12 heterodimer. The interaction between the two sets of
IL-12 and the receptor subunits forms the hexameric IL-12
signaling complex.52 The formation of the IL-12 signaling complex
brings the two interdependent Janus kinases into close proximity,
and the two kinases transactivate each other. Consequently, the
Janus kinases phosphorylate Tyr800 at the cytoplasmic region of
theb2 subunit that activates a STAT4 docking site. Upon activation
of the STAT4 docking site, the STAT4 SH2 domain binds to the
docking site, which enables the Janus kinases to phosphorylate the
C-terminal tail segment of STAT4. Then, the phosphorylated STAT4
dissociates from the IL-12 receptor complex. The SH2 domain
recognizes the phosphorylated tail segment of the other STAT4
dimer, and forms an active STAT4 tetramer.37 The active STAT4
tetramer will translocate to the nucleus to regulate the transcrip-
tion of IL-12 induced genes. This process of IL-12 signaling is
shown in the Supplementary Information (Figure S2: IL-12
signaling).
MSMD mutations in the IL-12 signaling genes
MSMD caused by IL-12 signaling mutations is autosome-
recessively inherited. Themajority of these patients have complete
deﬁciency of the corresponding gene, with the only exception
being an MSMD case caused by the mutation Cys198Arg.55 IL-12
signaling is important in the activation of natural killer (NK) cells
and T-cells, and in inducing Th1 immunity against mycobacterialis associated with TYK-2, and IL12Rb2 is associated with JAK-2. STAT4 exists in the
tive form of STAT4 is a tetramer.
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signaling deﬁciency, Mycobacterium-infected macrophages can
activate NK cells and a Th1 immune response to produce IFN-g by
an alternative pathway mediated by interleukin-18 (IL-18)
signaling.56 Therefore, compared to complete IFN-g signaling
deﬁciency, not all cases with complete IL-12 signaling deﬁciency
have MSMD.11,57 The immunodeﬁciency caused by the mutations
of IL12B and IL12RB1 is less speciﬁc for mycobacterial infection
than the IFN-g signaling mutations. For example, Salmonella
infection is also common and can be seen in 38% MSMD patients
with IL12B mutations57 and 62% patients with IL12RB1 muta-
tions.11 Other infections, such as Nocardia asteroides,57 Leishman-
ia,58 and fungus,59 have also been reported. The combined immune
deﬁciency may explain the poor prognosis of patients with IL-12
signaling mutations.
Mutation of TYK2 downstream of the IL-12 signaling
One mutation of the tyrosine kinase 2 gene (TYK2), encoding
TYK-2, has also been reported to result in generalized BCG
infection.60 A 4-bp deletion mutation c.209_212delGCTT causes a
shift in the protein reading frame from codon 70 and a premature
stop codon 20 amino acids downstream. Complete TYK-2
deﬁciency caused by this mutation interrupts IL-12 signaling
downstream of the ligand–receptor interaction and results in
susceptibility to generalized BCG infection. However, TYK-2
participates in the signaling of other cytokines as well, e.g., IFN-
a/b and interleukin-10 (IL-10). The immunodeﬁciency caused by
TYK-2 deﬁciency is therefore not speciﬁc for mycobacterial
infection. The patient is also highly susceptible to other viral
and fungal infections, and may suffer from atopic dermatitis with
elevated serum immunoglobulin E (IgE).60
Besides IL-12 signaling, the proteins encoded by IL12B, IL12RB1,
and TYK2, are also critical components of the IL-23 signaling
pathway and the development of the Th17 response.61,62
Therefore, impaired IL-23 signaling may also be involved in the
[(Figure_3)TD$FIG]
Figure 3. Nuclear factor kappa B essential modulator (NEMO) and NF-kB activation. NEM
signals and activates the IKK catalytic subunits Ikk-1 and Ikk-2. Activated IKK phosphory
NF-kB dimer translocates to the nucleus and regulates the transcription of target geneMSMD caused by these gene mutations and explain the non-
speciﬁcity of infections. However, no effect of IL-23 on the
production of IFN-g or IL-12 was suggested in a previous study.63
Another study suggested that the role of IL-23 signaling may be
less critical than that of IL-12 signaling in immunity against
mycobacterial infection.64
MSMD mutations in the IKBKG gene
Besides the genes involved in IFN-g and IL-12 signaling, a
mutation in the gene IKBKG (the inhibitor of kappa light
polypeptide gene enhancer in B-cells, kinase gamma) at chrXq28
has also been associated with MSMD.65 The protein encoded by
IKBKG is also known as NF-kB essential modulator (NEMO), and
mediates a critical NF-kB activation pathway. Inactive NF-kB
dimer in cytoplasm is bound by the inhibitory proteins, known as
the inhibitor ofkB (IkB). The activation of NF-kB ismediated by the
IkB kinase (IKK) complex, which phosphorylates IkB and induces
the ubiquitination of IkB. The IKK complex is comprised of two
catalytic subunits Ikk-1 and Ikk-2, the essential regulatory
subunits NEMO and ELKS, and other proteins.66 The role of NEMO
is to mediate cell surface signals to activate the IKK complex.67
Ubiquitinated IkB is degraded by the proteosomes in cytoplasm,
and active NF-kB dimer is released. Active NF-kB dimer
translocates to the nucleus and regulates the transcription of
NF-kB target genes (Figure 3).
NEMO-mediated NF-kB activation regulates the transcription
of a number of target genes involved in development and
immunity. Mutations causing complete NEMO deﬁciency cause
embryonic death in males and extremely skewed X inactivation
and familial incontinentia pigmenti in females.68 Mutations
causing partial NEMO deﬁciency (i.e., hypomorphic mutations)
have the phenotype of ectodermal dysplasia and immunodeﬁcien-
cy. The immunodeﬁciency caused by partial NEMO deﬁciency
involves both innate immunity, by impairing toll-like receptor
(TLR) signaling, and adaptive immunity. For the adaptive immuneO is a critical regulatory component of IkB kinase (IKK), which receives cell surface
lates IkB, and induces the degradation of IkB. Released by the inhibitory IkB, active
s.
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Such patients are susceptible to both pyogenic bacteria and
mycobacterial infection.70 Selective susceptibility to mycobacteri-
al infection has also been reported, associated with an X-linked
recessive MSMD.65 Empirically, the mutations leading to MSMD
have been shown to impair the production of IL-12.65 In addition,
NEMO mutations may also impair the production of IL-18.71 The
combined defect of impairing both IL-12 and IL-18 production can
explain the impaired IFN-g signaling and the speciﬁc mycobacte-
rial susceptibility. However, compared with the NEMO mutations
causing combined immunodeﬁciency, the NEMO mutations with
selective MSMD phenotype have a less serious impact on NEMO
gene function. The selective susceptibilitymay reﬂect the necessity
of intact innate and adaptive immunity for protection against
mycobacterial infection.
Summary
The genetic studies ofMSMDdemonstrate a complexmolecular
network involved in the immunity to mycobacterial infection
(Figure 4). After phagocytizing MTB, proinﬂammatory macro-
phages present mycobacterial antigens to CD4+ T-lymphocytes
and secrete IL-12.72 The HLA class II molecules on the surfaces of
macrophages present mycobacterial antigens to the T-cell
receptors (TCR) on the surfaces of CD4+ T-cells. NEMO-mediated
NF-kB activation regulates both IL-12 secretion in macrophages
and the TCR signaling in CD4+ T-cells. Partial NEMO deﬁciency can
result in selective susceptibility to mycobacterial infection.
IL-12 signaling induces the generation of Th1 cells from
antigen-activated naı¨ve CD4+ T-cells. Complete IL-12 signaling
deﬁciency by either IL12B or IL12RB1 mutations, has low
penetrance and a better prognosis in MSMD, which suggests that
macrophages can induce a Th1 response independent of IL-12.
Complete IL-12 signaling deﬁciency is not speciﬁc tomycobacterial
[(Figure_4)TD$FIG]
Figure 4. Molecular mechanisms of immunity to mycobacteria revealed by
immunogenetic studies.infection, and Salmonella infection is common. These facts suggest
that IL-12 signaling plays important, but not central, roles in
antimycobacterial immunity. Downstream TYK-2 mediates the
signaling of IL-12, as well as other cytokines, such as IFN-a/b and
IL-10. Complete TYK-2 deﬁciency results in susceptibility to
mycobacterial, viral, and fungal infections, as well as atopic
dermatitis with elevated serum IgE.
Activated Th1 cells secrete IFN-g. IFN-g signaling provides
positive feedback to both macrophages and CD4+ T-cells, which
ampliﬁes the Th1 response. Complete IFN-g signaling deﬁciency
caused by mutations of the IFN-g receptor genes, IFNGR1 or
IFNGR2, is highly speciﬁc for mycobacterial infection. Downstream
STAT1 mediates the signaling of IFN-g, as well as IFN-a/b.
Complete or partial STAT1 deﬁciency caused by homozygous
mutations results in susceptibility to both mycobacterial and viral
infections. Only dominant negative mutations of STAT1 have
speciﬁc susceptibility tomycobacterial infection, depending on the
different functional modes of STAT1 in the signaling of IFN-g and
IFN-a/b. This evidence demonstrates that IFN-g signaling plays a
central role in antimycobacterial immunity.
Concerning the critical roles of IFN-g in the Th1 response, the
genetic ﬁndings in the MSMD studies may also shed light on the
molecular genetics studies of other infectious diseases where the
Th1 response plays a key role. Recent studies have demonstrated
that IFNGR1 mutation may cause fungal infections, such as
coccidiomycosis and histoplasmosis in humans73,74 and Crypto-
coccus infection inmice.75 It has also been suggested that common
DNA polymorphisms of IFNGR1 and IFNGR2 are associated with
susceptibility in malaria,76 hepatitis B,77 hepatitis C,78 human
immunodeﬁciency virus (HIV) infection,79 and leishmaniasis.80
Themolecular network highlighted by theMSMD studies warrants
further study in these infectious diseases.
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